Horace Mann Educators HMN Cancer — Liability for Future Policy Benefit, after Reinsurance

Other product segments

Similar metrics at other companies

AFLCancer — Liability for Future Policy Benefit, after Reinsurance

$17.28B-20.7%

AFLCancer — Liability for Future Policy Benefit, Expected Future Policy Benefit, before Reinsurance, after Discount Rate Change

3,293,600,000,000%-850,200,000,000pp

AFLCancer — Liability for Future Policy Benefit, Expected Future Policy Benefit, Undiscounted, before Reinsurance

$53.31B-11.0%

AFLCancer — Liability for Future Policy Benefit, Expected Net Premium, before Reinsurance, after Discount Rate Change

1,151,800,000,000%-297,800,000,000pp

AFLCancer — Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance

3,540,600,000,000%-449,400,000,000pp

EQHHealth — Liability for Future Policy Benefit, after Reinsurance

$283M-3.4%

Questions, answered.

What is Horace Mann Educators's cancer — liability for future policy benefit, after reinsurance?

Horace Mann Educators (HMN) reported cancer — liability for future policy benefit, after reinsurance of $64.4M in Q1 2026.

How has Horace Mann Educators's cancer — liability for future policy benefit, after reinsurance changed year-over-year?

Horace Mann Educators's cancer — liability for future policy benefit, after reinsurance decreased by 10.7% year-over-year, from $72.1M to $64.4M.

What is the long-term trend for Horace Mann Educators's cancer — liability for future policy benefit, after reinsurance?

Over 2 years (2023 to 2025), Horace Mann Educators's cancer — liability for future policy benefit, after reinsurance has grown at a -15.0% compound annual growth rate (CAGR), from $380.2M to $274.8M.

What does cancer — liability for future policy benefit, after reinsurance mean?

This metric represents the net actuarial estimate of the present value of future benefits payable to policyholders under cancer-specific supplemental health insurance contracts, adjusted for reinsurance recoverables. It reflects the company's long-term financial obligation to cover future claims for this specific product line, accounting for expected mortality, morbidity, and lapse rates. Monitoring this liability is essential for assessing the adequacy of reserves and the long-term profitability of the supplemental health insurance segment.